Cephalosporin Drugs Market: By Generation (First-generation, Second-generation, Third-generation, Fourth-generation, Fifth-generation), By Drug Type (Generic, Branded), By Route of Administration (Oral, Injection), By Application (Respiratory Tract Infections, Urinary Tract Infections, Sexually Transmitted Infections, Skin Infections, Others) By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography.  

Purchase Option

$ 4400
$ 6600
$ 8900

Cephalosporin Drugs Market size was valued at USD 14.7 billion in 2022 and is poised to grow at a CAGR of 2.9% from 2023-29. The cephalosporin drugs market plays a pivotal role in the pharmaceutical industry, offering a diverse range of antibiotics that are crucial in combating bacterial infections. Cephalosporin drugs belong to the beta-lactam class of antibiotics and are widely used to treat a variety of infections ranging from mild to severe. Their effectiveness against both Gram-positive and Gram-negative bacteria has made them indispensable in clinical settings. Cephalosporin drugs find application in treating infections of the respiratory tract, urinary tract, skin, soft tissues, and even more serious conditions like septicemia and meningitis. According to WHO, respiratory tract infections are a leading cause of morbidity in Europe, with over 300 million reported cases annually. Urinary tract infections (UTIs) are a major concern in the USA, affecting 150 million individuals yearly as reported by WHO. Skin and soft tissue infections contribute significantly to the disease burden, with Europe witnessing around 12 million cases each year according to WHO. Septicemia, a life-threatening condition, accounts for an estimated 6 million cases globally, with the USA recording a substantial portion. WHO states that meningitis affects approximately 1.2 million people worldwide annually, with Europe and the USA observing notable instances. The cephalosporin drugs market is influenced by several dynamics. Drivers include the rising prevalence of bacterial infections due to aging populations, increased surgeries, and antibiotic-resistant strains. Technological advancements in drug delivery enhance cephalosporin drug administration's efficacy. However, stringent regulations and potential side effects impede market growth. Nevertheless, opportunities arise from ongoing R&D for novel formulations, potentially improving therapeutic outcomes. Increased awareness of proper antibiotic use could drive long-term demand. Despite this, threats persist. Antibiotic resistance remains a challenge, demanding continuous innovation. Competition from alternatives and generic versions could affect market share and profitability, highlighting the need for strategic positioning and innovation in the cephalosporin drugs market.

Cephalosporin Drugs Market Key Developments:
  • In March 2017, Pfizer, Inc. launched a new cephalosporin drug Zavicefta in the U.K to treat serious aerobic Gram-negative infections caused by resistant bacteria. 
  • In November 2015, Merck MSD launched a new antibiotic Zerbaxa (ceftolozane/tazobactam) in the U.K. to treat complicated intra-abdominal and urinary tract infections and acute pyelonephritis

Cephalosporin Drugs Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

2.90%

Largest Market

North America

Fastest Growing Market

Asia Pacific
Cephalosporin Drugs Market Dynamics

Increase in the incidence of bacterial infectious diseases such as urinary tract infections, respiratory tract infections, sexually transmitted infections, and other bacterial infections are anticipated to fuel the cephalosporin drugs market over the forecast years. For instance, according to WHO 2016, approximately more than 340 Mn new sexually transmitted disease cases are acquired per year around the globe. Moreover, increase in the R&D expenditure for the development of newer drugs, and rise in disposable income are anticipated to surge the global cephalosporin drugs market over the forecast timeframe.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market, and forecast (2018-2022 to 2023-29)
  • The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and startup's details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
  • The report analyses the impact of the socio-political environment through PESTLE Analysis and competition through Porter's Five Force Analysis in addition to recent technology advancements and innovations in the market

Cephalosporin Drugs Market Segmentation

By Generation
  • First-generation
  • Second-generation
  • Third-generation
  • Fourth-generation
  • Fifth-generation
By Drug Type
  • Generics
  • Branded
By Route-administration
  • Oral
  • Injection

Frequently Asked Questions

The cephalosporin drugs market size was valued at USD 14.71 billion in 2022

The cephalosporin drugs market key players are Allergan Plc (U.K.) Bristol-Myers Squibb Company (U.S.) Eli Lilly and Company (U.S.) Hoffmann-La Roche Ltd. (Switzerland) GlaxoSmithKline Plc (U.K.) Lupin Limited (India) Merck & Co., Inc. (U.S.) Pfizer Inc. (U.S.) Sanofi S.A. (France) Teva Pharmaceutical Industries Ltd. (Israel)

The cephalosporin drugs market regions classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.

1. Executive Summary

2. Global Cephalosporin Drugs Market Introduction

2.1. Global Cephalosporin Drugs Market - Taxonomy

2.2. Global Cephalosporin Drugs Market -Definitions

2.2.1. By Generation

2.2.2. By Drug Type

2.2.3. By Route of Administration

2.2.4. By Application

3. Global Cephalosporin Drugs Market Dynamics

3.1. Drivers

3.2. Restraints

3.3. Opportunities/Unmet Needs of the Market

3.4. Trends

3.5. Global Cephalosporin Drugs Market Dynamics - Factors Impact Analysis

3.6. Global Cephalosporin Drugs Market - Competition Landscape

3.7. Epidemiology

4. Global Cephalosporin Drugs Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029

4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)

4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

4.3. Market Opportunity Analysis

5. Global Cephalosporin Drugs Market Forecast, By Generation , 2018 - 2022 and Forecast, 2023 - 2029

5.1. First Generation

5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)

5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.1.3. Market Opportunity Analysis

5.2. Second Generation

5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)

5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.2.3. Market Opportunity Analysis

5.3. Third Generation

5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)

5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.3.3. Market Opportunity Analysis

5.4. Fourth Generation

5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)

5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.4.3. Market Opportunity Analysis

5.5. Fifth Generation

5.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)

5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.5.3. Market Opportunity Analysis

6. Global Cephalosporin Drugs Market Forecast, By Drug Type, 2018 - 2022 and Forecast, 2023 - 2029

6.1. Generics

6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)

6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.1.3. Market Opportunity Analysis

6.2. Branded

6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)

6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.2.3. Market Opportunity Analysis

7. Global Cephalosporin Drugs Market Forecast, By Route of Administration, 2018 - 2022 and Forecast, 2023 - 2029

7.1. Oral

7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)

7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.1.3. Market Opportunity Analysis

7.2. Injection

7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)

7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.2.3. Market Opportunity Analysis

8. Global Cephalosporin Drugs Market Forecast, By Application, 2018 - 2022 and Forecast, 2023 - 2029

8.1. Respiratory Tract Infections

8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)

8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.1.3. Market Opportunity Analysis

8.2. Urinary Tract Infections

8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)

8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.2.3. Market Opportunity Analysis

8.3. Sexually Transmitted Infections

8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)

8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.3.3. Market Opportunity Analysis

8.4. Skin Infections

8.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)

8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.4.3. Market Opportunity Analysis

8.5. Others

8.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)

8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.5.3. Market Opportunity Analysis

9. Global Cephalosporin Drugs Market Forecast, By Distribution Channel, 2018 - 2022 and Forecast, 2023 - 2029

9.1. Hospital Pharmacies

9.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)

9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

9.1.3. Market Opportunity Analysis

9.2. Retail Pharmacies

9.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)

9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

9.2.3. Market Opportunity Analysis

9.3. Online Pharmacies

9.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)

9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

9.3.3. Market Opportunity Analysis

10. Global Cephalosporin Drugs Market Forecast, By Region, 2018 - 2022 and Forecast, 2023 - 2029

10.1. North America

10.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)

10.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

10.1.3. Market Opportunity Analysis

10.2. Europe

10.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)

10.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

10.2.3. Market Opportunity Analysis

10.3. Asia Pacific

10.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)

10.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

10.3.3. Market Opportunity Analysis

10.4. Latin America

10.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)

10.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

10.4.3. Market Opportunity Analysis

10.5. The Middle East & Africa

10.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)

10.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

10.5.3. Market Opportunity Analysis

10.6. Global Cephalosporin Drugs Market - Opportunity Analysis Index, By Generation, By Drug Type, By Route of Administration, By Application, By Distribution Channel, and Region, 2023 - 2029

11. North America Cephalosporin Drugs Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029

11.1. Generation Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

11.1.1. First-generation

11.1.2. Second-generation

11.1.3. Third-generation

11.1.4. Fourth-generation

11.1.5. Fifth-generation

11.2. Drug Type Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

11.2.1. Generic

11.2.2. Branded

11.3. Route of Administration Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

11.3.1. Oral

11.3.2. Injection

11.4. Application Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

11.4.1. Respiratory Tract Infections

11.4.2. Urinary Tract Infections

11.4.3. Sexually Transmitted Infections

11.4.4. Skin Infections

11.4.5. Others

11.5. Distribution Channel Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

11.5.1. Hospital Pharmacies

11.5.2. Retail Pharmacies

11.5.3. Online Pharmacies

11.6. Country Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

11.6.1. U.S.

11.6.2. Canada

11.7. North America Cephalosporin Drugs Market - Opportunity Analysis Index, By Generation, By Drug Type, By Route of Administration, By Application, By Distribution Channel, and Country, 2023 - 2029

11.8. North America Cephalosporin Drugs Market Dynamics - Trends

12. Europe Cephalosporin Drugs Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029

12.1. Generation Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

12.1.1. First-generation

12.1.2. Second-generation

12.1.3. Third-generation

12.1.4. Fourth-generation

12.1.5. Fifth-generation

12.2. Drug Type Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

12.2.1. Generic

12.2.2. Branded

12.3. Route of Administration Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

12.3.1. Oral

12.3.2. Injection

12.4. Application Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

12.4.1. Respiratory Tract Infections

12.4.2. Urinary Tract Infections

12.4.3. Sexually Transmitted Infections

12.4.4. Skin Infections

12.4.5. Others

12.5. Distribution Channel Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

12.5.1. Hospital Pharmacies

12.5.2. Retail Pharmacies

12.5.3. Online Pharmacies

12.6. Country Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

12.6.1. Germany

12.6.2. UK

12.6.3. France

12.6.4. Spain

12.6.5. Italy

12.6.6. Russia

12.6.7. Poland

12.6.8. Rest of Europe

12.7.  Europe Cephalosporin Drugs Market - Opportunity Analysis Index, By Generation, By Drug Type, By Route of Administration, By Application, By Distribution Channel, and Country, 2019 - 2025

12.8. Europe Cephalosporin Drugs Market Dynamics - Trends

13. Asia Pacific Cephalosporin Drugs Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029

13.1. Generation Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

13.1.1. First-generation

13.1.2. Second-generation

13.1.3. Third-generation

13.1.4. Fourth-generation

13.1.5. Fifth-generation

13.2. Drug Type Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

13.2.1. Generic

13.2.2. Branded

13.3. Route of Administration Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

13.3.1. Oral

13.3.2. Injection

13.4. Application Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

13.4.1. Respiratory Tract Infections

13.4.2. Urinary Tract Infections

13.4.3. Sexually Transmitted Infections

13.4.4. Skin Infections

13.4.5. Others

13.5. Distribution Channel Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

13.5.1. Hospital Pharmacies

13.5.2. Retail Pharmacies

13.5.3. Online Pharmacies

13.6. Country Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

13.6.1. Japan

13.6.2. China

13.6.3. India

13.6.4. ASEAN

13.6.5. Australia & New Zealand

13.6.6. Rest of Asia-Pacific

13.7. Asia Pacific Cephalosporin Drugs Market - Opportunity Analysis Index, By Generation, By Drug Type, By Route of Administration, By Application, By Distribution Channel, and Country, 2019 - 2025

13.8. Asia Pacific Cephalosporin Drugs Market Dynamics - Trends

14. Latin America Cephalosporin Drugs Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029

14.1. Generation Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

14.1.1. First-generation

14.1.2. Second-generation

14.1.3. Third-generation

14.1.4. Fourth-generation

14.1.5. Fifth-generation

14.2. Drug Type Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

14.2.1. Generic

14.2.2. Branded

14.3. Route of Administration Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

14.3.1. Oral

14.3.2. Injection

14.4. Application Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

14.4.1. Respiratory Tract Infections

14.4.2. Urinary Tract Infections

14.4.3. Sexually Transmitted Infections

14.4.4. Skin Infections

14.4.5. Others

14.5. Distribution Channel Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

14.5.1. Hospital Pharmacies

14.5.2. Retail Pharmacies

14.5.3. Online Pharmacies

14.6. Country Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

14.6.1. Mexico

14.6.2. Brazil

14.6.3. Argentina

14.6.4. Venezuela

14.6.5. Rest of Latin America

14.7. Latin America Cephalosporin Drugs Market - Opportunity Analysis Index, By Generation, By Drug Type, By Route of Administration, By Application, By Distribution Channel, and Country, 2019 - 2025

14.8. Latin America Cephalosporin Drugs Market Dynamics - Trends

15. Middle East and Africa Cephalosporin Drugs Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029

15.1. Generation Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

15.1.1. First-generation

15.1.2. Second-generation

15.1.3. Third-generation

15.1.4. Fourth-generation

15.1.5. Fifth-generation

15.2. Drug Type Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

15.2.1. Generic

15.2.2. Branded

15.3. Route of Administration Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

15.3.1. Oral

15.3.2. Injection

15.4. Application Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

15.4.1. Respiratory Tract Infections

15.4.2. Urinary Tract Infections

15.4.3. Sexually Transmitted Infections

15.4.4. Skin Infections

15.4.5. Others

15.5. Distribution Channel Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

15.5.1. Hospital Pharmacies

15.5.2. Retail Pharmacies

15.5.3. Online Pharmacies

15.6. Country Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

15.6.1. GCC Countries

15.6.2. South Africa

15.6.3. Israel

15.6.4. Rest of MEA

15.7. Middle East and Africa Cephalosporin Drugs Market - Opportunity Analysis Index, By Generation, By Drug Type, By Route of Administration, By Application, By Distribution Channel, and Country, 2019 - 2025

15.8. Middle East and Africa Cephalosporin Drugs Market Dynamics - Trends

16. Competition Landscape

16.1. Strategic Dashboard of Top Market Players

16.2. Company Profiles (Introduction, Financial Analysis, Key Developments, Strategies, and SWOT Analysis)

16.2.1. Allergan Plc (U.K.)

16.2.2. Bristol-Myers Squibb Company (U.S.)

16.2.3. Eli Lilly and Company (U.S.)

16.2.4. F. Hoffmann-La Roche Ltd. (Switzerland)

16.2.5. GlaxoSmithKline Plc (U.K.)

16.2.6. Lupin Limited (India)

16.2.7. Merck & Co., Inc. (U.S.)

16.2.8. Pfizer Inc. (U.S.)

16.2.9. Sanofi S.A. (France)

16.2.10. Teva Pharmaceutical Industries Ltd. (Israel)

17. Research Methodology

18. Key Assumptions and Acronyms

  • Allergan Plc (U.K.)
  • Bristol-Myers Squibb Company (U.S.)
  • Eli Lilly and Company (U.S.)
  • Hoffmann-La Roche Ltd. (Switzerland)
  • GlaxoSmithKline Plc (U.K.)
  • Lupin Limited (India)
  • Merck & Co., Inc. (U.S.)
  • Pfizer Inc. (U.S.)
  • Sanofi S.A. (France)
  • Teva Pharmaceutical Industries Ltd. (Israel)

Adjacent Markets

VEGFR-1 Inhibitors Market
Uveal Melanoma Market
TYK2 Inhibitors Market
Viral Protein Inhibitor Market
TRAIL R2 Agonists Market
Music Therapy Market